{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:02:45Z","timestamp":1777878165373,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,12,27]],"date-time":"2015-12-27T00:00:00Z","timestamp":1451174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>The use of anti-CD20 monoclonal antibodies (mAbs), such as rituximab, in CD20-positive B-cell malignancies has dramatically improved the outcome of chronic lymphoid leukemia and non-Hodgkin\u2019s lymphomas (NHL). However, the occurrence of relapse and development of rituximab-refractory disease highlight the need to develop novel anti-CD20 mAbs, with improved mechanisms of action. Obinutuzumab is the first humanized type II glycoengineered anti-CD20 mAb. In vitro and in vivo data suggested several differences compared with rituximab, including a low level of complement-dependent cytotoxicity and an increased direct nonapoptotic cell death. Moreover, the glycoengineered Fc-linked nonfucosylated oligosaccharide enhanced the Fc\u2013Fc\u03b3 receptor (Fc\u03b3R) IIIa interaction, resulting in improved antibody-dependent cellular cytotoxicity and phagocytosis. Preclinical models suggested that these differences translate into superior survival in murine lymphoma models. Phase I\/II trials in monotherapy in relapsed or refractory B-cell NHL demonstrated that obinutuzumab has an acceptable safety profile, infusion-related reactions being the most common adverse event. In rituximab-refractory indolent NHL, the recent randomized phase III GADOLIN study demonstrated an improved median progression-free survival for patients treated with obinutuzumab plus bendamustine rather than bendamustine alone. Further trials are ongoing to determine the role of obinutuzumab as a first-line agent in the treatment of follicular lymphoma.<\/jats:p>","DOI":"10.1177\/2040620715622613","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T20:43:41Z","timestamp":1451335421000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Obinutuzumab for relapsed or refractory indolent non-Hodgkin\u2019s lymphomas"],"prefix":"10.1177","volume":"7","author":[{"given":"Ludovic","family":"Gabellier","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie Clinique, Centre Hospitalier R\u00e9gional Universitaire de Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie Clinique, Centre Hospitalier R\u00e9gional Universitaire, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 05, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,12,27]]},"reference":[{"key":"bibr1-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"key":"bibr2-2040620715622613","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000303"},{"key":"bibr3-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.09.004"},{"key":"bibr4-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"bibr5-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1292"},{"key":"bibr6-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"bibr7-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"bibr8-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031"},{"key":"bibr9-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1761"},{"key":"bibr10-2040620715622613","first-page":"687","volume":"114","author":"Craigen J.","year":"2009","journal-title":"Blood (ASH Ann Meet Abstr)"},{"key":"bibr11-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1254"},{"key":"bibr12-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0385"},{"key":"bibr13-2040620715622613","first-page":"611","volume":"5","author":"Davis T.","year":"1999","journal-title":"Clin Cancer Res"},{"key":"bibr14-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06974.x"},{"key":"bibr15-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0850"},{"key":"bibr16-2040620715622613","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini M.","year":"2005","journal-title":"Ann Oncol"},{"key":"bibr17-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504043"},{"key":"bibr18-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2008.10.004"},{"key":"bibr19-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"bibr20-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"bibr21-2040620715622613","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301249"},{"key":"bibr22-2040620715622613","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.856008"},{"key":"bibr23-2040620715622613","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann W.","year":"2005","journal-title":"Blood"},{"key":"bibr24-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185280"},{"key":"bibr25-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175208"},{"key":"bibr26-2040620715622613","doi-asserted-by":"publisher","DOI":"10.2165\/11201110-000000000-00000"},{"key":"bibr27-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-009480"},{"key":"bibr28-2040620715622613","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"bibr29-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330357"},{"key":"bibr30-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2011.01552.x"},{"key":"bibr31-2040620715622613","first-page":"390","volume":"96","author":"Morschhauser F.","year":"2011","journal-title":"Haematologica"},{"key":"bibr32-2040620715622613","first-page":"4458","volume":"124","author":"Morschhauser F.","year":"2014","journal-title":"Blood (ASH Ann Meet Abstr)"},{"key":"bibr33-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"bibr34-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305847"},{"key":"bibr35-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"bibr36-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12040"},{"key":"bibr37-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08428.x"},{"key":"bibr38-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481341"},{"key":"bibr39-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200337"},{"key":"bibr40-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"bibr41-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9718"},{"key":"bibr42-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408773"},{"key":"bibr43-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.18_suppl.lba8502"},{"key":"bibr44-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"bibr45-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009483200"},{"key":"bibr46-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202069200"},{"key":"bibr47-2040620715622613","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400288"},{"key":"bibr48-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0066"},{"key":"bibr49-2040620715622613","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620715622613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620715622613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620715622613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:13:34Z","timestamp":1777590814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620715622613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,27]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1177\/2040620715622613"],"URL":"https:\/\/doi.org\/10.1177\/2040620715622613","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,27]]}}}